



Visionary Innovation

AGM Information Session

May 11, 2026



Safe Harbor Statements

Cautionary note on forward-looking statements

These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward-looking statements. For example, all statements we make regarding the initiation, timing, progress and results of our preclinical studies, our clinical studies, our research and development programs, our regulatory strategy, market opportunities, our future development plans, our ability to advance product candidates into, and successfully complete clinical studies, and the timing or likelihood of regulatory filings and approvals and statements regarding the potential therapeutic benefits of our product candidates are forward looking. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: the possibility that Oculis may be adversely affected by economic, business, and/or competitive factors; Oculis' estimates of expenses and profitability; Oculis' ability to develop, manufacture and commercialize the product candidates in its pipeline; actions of regulatory authorities, which may affect the initiation, timing and progress of clinical studies or future regulatory approvals or marketing authorizations; the ability of Oculis or its partners to enroll and retain patients in clinical studies; the ability of Oculis or its partners to gain approval from regulators for planned clinical studies, study plans or sites; Oculis' ability to obtain and maintain regulatory approval or authorizations of its products, including the timing or likelihood of expansion into additional markets or geographies; the success of Oculis' current and future collaborations, joint ventures, partnerships or licensing arrangements; financial position, strategy and anticipated milestones; and other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in documents that Oculis may from time to time file or furnish with the SEC. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Overview

1. Registration and Voting
2. Business Update
3. Financial Update
4. Q&A Session 1
5. 2026 AGM – Agenda Items and Proposals
6. 2026 AGM – Attending, Voting, Viewing
7. Q&A Session 2

1. Registration for Voting

Attending, Voting and Viewing the Annual General Meeting

Attending and Voting in Person at the Annual General Meeting

- AGM is at 12:00 p.m. CEST on 13 May 2026.
- Location: Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland
- Shareholders wishing to attend and vote at the 2026 Annual General Meeting in person must present proof of ownership (or a valid legal proxy) and a valid government issued identification document at the 2026 Annual General Meeting.

Voting through proxy / providing electronic voting instructions

- Shares held on Nasdaq US: Managed by Broadridge
- Shares held on Nasdaq Iceland: Voting through Lumi AGM Mobile Platform

Broadcast

- The 2026 Annual General Meeting will be broadcast for viewing only, with no option for virtual participation.
- View AGM broadcast through Lumi: <https://meetings.lumiconnect.com/100-352-684-319>

Voting through proxy / providing electronic voting instructions

	Shares held on Nasdaq US		Shares held on Nasdaq Iceland
Managed by	Broadridge		Lumi AGM Mobile Platform
Ownership type	Shares held via broker	Shares held directly (registered/Continental)	n/a
How you receive voting info	Via broker (email/letter with Broadridge link)	By email/letter from Broadridge	Register for voting on: www.lumiconnect.com/events/oculisagm2026
How you vote	1) Online on proxyvote.com using control number received along with voting information 2) By sending proxy by mail to Broadridge		Online using login credentials received by e-mail after registration is confirmed by Lumi
Deadline	Voting instructions must be received by Broadridge no later than 23:59 EDT on 11 May 2026		Submit voting instructions by 23:59 EDT on 11 May 2026 on the Lumi platform

2. Business Update

Successful 2025 Powering Transformative 2026


Pipeline:

- ✓ Significant advancements across all three late-stage assets
- ✓ **OCS-01** DIAMOND Phase 3 program >800 patients with DME; Focused execution and on-track for topline readout in June
- ✓ **Licaminlimab** precision medicine approach for DED gained FDA alignment; PREDICT-1 registrational trial topline readout anticipated in Q4 2026
- ✓ **Privosegtor** gained Breakthrough Therapy designation (FDA), Priority Medicines (PRIME) designation (EMA), and Special Protocol Assessment (SPA) alignment with FDA; establishing clear regulatory pathway for ON

Financial and talent capital:

- ✓ Strong balance sheet, no debt, and current cash runway into 1H 2029, excluding a CHF100m loan facility
- ✓ Expanded senior leadership team with relevant and extensive experience to drive quality and timely execution and results delivery

Topline Results from Both DIAMOND Phase 3 Trials Expected in June 2026



OCS-01 **NDA submission approval** for DME anticipated

Q4 2027

OCS-01 **NDA submission** for DME planned

Q4 2026

DIAMOND **Phase 3 trials topline results** in DME anticipated

June 2026

Last patient visit completed in DIAMOND Phase 3 program


April 2026

119 sites activated
>800 patients randomized

Privosegtor, a Breakthrough Therapy and PRIME Designated Candidate, in Global Registrational PIONEER Program in Optic Neuropathies




Three Registrational trials in optic neuritis and NAION



PIONEER studies run concurrently to create operational synergies, improve cost efficiency, and accelerate development timelines

Oculis Pipeline Development Strategic Evolution



DME diabetic macular edema, DED: dry eye disease, NAION: Non-arteritic Anterior Ischemic Optic Neuropathy MS: Multiple Sclerosis.

1. DR and DME Disease and Landscape report Nov. 2020 – 2024 market value estimate for G7, 2. DED Disease and Landscape report 2020 - 2024 market value estimate for G7, 3. MS Disease and Landscape report October 2024 – 2024 market value estimate for G7, 4. Optic nerve disorders, Transparency Market Research, 5. Global Market Insights, March 2024 <https://www.gminsights.com/industry-analysis/neuroprotection-market>

A Catalyst-rich 12-month Horizon Driven by Three Core Transformative Assets in Active Registrational Programs

	Candidate	Phase 1	Phase 2	Phase 3	Value Catalysts
OPHTHALMOLOGY	OCS-01 OPTIREACH®	Diabetic Macular Edema			DIAMOND-1 & DIAMOND-2 topline readout June 2026 NDA submission for DME in Q4 2026
	Licaminlimab	Dry Eye Disease			Started PREDICT-1 registrational trial in Q4 2025 Topline readout from PREDICT-1 in Q4 2026
NEURO-OPHTHALMOLOGY		Optic Neuritis	<u>Breakthrough Therapy and PRIME designations</u>		Started PIONEER-1 registrational trial in Q4 2025 Start of PIONEER-2 registrational trial in 1H 2026
	Privosegtor	NAION			Start of PIONEER-3 registrational trial in Mid 2026
		Multiple Sclerosis Relapses			Cross-reference Optic Neuritis IND for new IND submission in MS Relapses in 2H 2026

Privosegtor, OCS-01 and Licaminlimab are investigational drugs, their safety or efficacy has not been established, and they have not received regulatory approval for commercial use in any country.

3. Financial Update

2025 Key Financial Highlights

- **Cash Position:** held cash equivalents and short-term investments of CHF 213.0 million (\$268.7 million), compared to CHF 98.7 million (\$109.0 million) as of December 31, 2024. Increase primarily due to equity financings gross proceeds of \$210.0 million (CHF 178.9 million).
- **Research and development expenses:** 69% of total operating expenses. CHF 57.1 million (\$68.7 million), compared to CHF 52.1 million (\$59.1 million) in FY2024. Increase driven by OCS-01 DIAMOND program with 119 U.S. and international sites and >800 patients; Topline readout anticipated in June 2026
- **FY2025 net loss:** CHF 99.0 million or \$119.1 million, compared to CHF 85.8 million (\$97.4 million) for FY2024. Increase was primarily due to OCS-01 Phase 3 DIAMOND trials, increased personnel costs, and non-cash fx and warrant market-to-market adjustments.

Note: Data from 2025 Form 20-F

4. Q&A Session 1

5. 2026 AGM - Agenda Items and Proposals

Agenda Item 1.

Approval of the 2025 Annual Report including the 2025 Annual (Statutory) Financial Statements and the 2025 Consolidated Financial Statements

The Board proposes the approval of the annual report including the annual financial statements for the business year 2025 and the consolidated financial statements for the business year 2025.

Agenda Item 2.

Allocation of Balance Sheet Results 2025

The Board proposes that the balance sheet loss of CHF 80'247'000 be carried forward to the new accounts.

Net loss for the business year 2025	CHF 33'670'000
-------------------------------------	----------------

Accumulated loss brought forward	CHF 80'247'000
----------------------------------	----------------

Agenda Item 3.

Discharge to the Members of the Board of Directors and the Executive Committee

The Board proposes that a full discharge be granted to all members of the Board of Directors and the Executive Committee for their activities in 2025.

Agenda Item 4.

Election of the Chairperson and the other Members of the Board of Directors

The term of office of the Chairperson and all current members of the Board of Directors expires at the end of the 2026 Annual General Meeting. The Board of Directors proposes the re-election of the current members of the Board of Directors, including the Chairperson, and the election of a new Board member, Gregory D. Perry, each with a term until the end of the 2027 Annual General Meeting.

Agenda Item 5.

Election of the Members of the Compensation Committee

The Board of Directors proposes the election of Lionel Carnot, Geraldine O’Keeffe and Gregory D. Perry as members of the Compensation Committee, each until the end of the 2027 Annual General Meeting.

Agenda Item 6.

Re-election of the Auditors

The Board of Directors proposes to re-elect PricewaterhouseCoopers SA, in Lausanne, Switzerland, as the Company's statutory auditors for a term of office of one year.

Agenda Item 7.

Election of the Independent Proxy

The Board of Directors proposes to elect Blum & Partner AG, in Zug, Switzerland, as the Company's independent proxy until the end of the 2027 Annual General Meeting.

Agenda Item 8.

Compensation for the Non-Executive Members of the Board of Directors

8.1. Vote on Total Fixed (Non-Performance-Related) Compensation for Non-Executive Members of the Board of Directors until the end of the Company's 2027 Annual General Meeting

The Board of Directors proposes the approval of a total maximum amount of fixed (non-performance-related) compensation for eight non-executive members of the Board of Directors for the period from the Company's 2026 Annual General Meeting to the Company's 2027 Annual General Meeting of USD 572'000.

8.2. Vote on Equity or Equity Based Compensation for Non-Executive Members of the Board of Directors until the end of the Company's 2027 Annual General Meeting

The Board of Directors proposes the approval of the grant of options with share equivalent, shares or equity linked instruments for eight non-executive members of the Board of Directors for the period until the end of the Company's 2027 Annual General Meeting, with a then current maximum value of all equity or equity linked instruments of USD 2'150'000 (excluding employer social security and pension contributions).

Agenda Item 9.

Compensation for the Members of the Executive Committee

9.1. Vote on Fixed (Non-Performance-Related) Compensation for Members of the Executive Committee payable in 2027

The Board of Directors proposes to approve a total maximum amount of fixed (non-performance-related) compensation for three members of the Executive Committee for the calendar year 2027 and payable in 2027 of USD 2'500'000.

9.2. Vote on Variable Compensation for Members of the Executive Committee payable in 2027

The Board of Directors proposes to approve a total maximum amount of variable compensation for three members of the Executive Committee for the calendar year 2026 and payable in 2027 of USD 1'800'000.

9.3. Vote on Equity Based Compensation for Members of the Executive Committee for 2027

The Board of Directors proposes to approve the grant of options with share equivalent, shares or equity linked instruments for three members of the Executive Committee for grants until the end of the calendar year 2027, with a then current maximum value of all options, shares or equity linked instruments of USD 18'000'000 (excluding employer social security and pension contributions).

Agenda Item 10.

Non-binding Advisory Vote on the 2025 Compensation Report

The Board of Directors proposes the approval on a consultative basis (non-binding advisory vote) of the 2025 Compensation Report.

Agenda Item 11.

Increase and Amendment of Capital Band

The Board of Directors proposes to (i) adapt the existing paragraphs 1 through 3 of article 3a (*Capital Band*) of the articles of association pertaining to capital band, (ii) create capital band between CHF 620'417.76 (lower limit) and CHF 930'626.64 (upper limit), (iii) authorize the Board of Directors to increase the Company's share capital up to the upper limit at any time and as often as required until 13 May 2031 by issuing a maximum of 31'020'888 registered shares with a par value of CHF 0.01 each, to be fully paid up, and (iv) amend the paragraphs 1 through 3 of article 3a of the articles of association as set out in the invitation to the 2026 Annual General Meeting.

Agenda Item 12.

Increase of Conditional Share Capital for Employee Benefit Plans

The Board of Directors proposes to (i) adapt the existing first paragraph of article 3c (*Conditional Capital Increase for Employee Benefit Plans*) of the articles of association pertaining to the conditional capital increase for employees and individuals of comparable positions, (ii) create conditional share capital for the same purpose in the maximum amount of CHF 126'777.00 by the issuance of 12'677'700 registered common shares of CHF 0.01 nominal value each and (iii) amend article 3c, paragraph 1 of the articles of association as set out in the invitation to the 2026 Annual General Meeting.

6. 2026 AGM – Attending, Voting, Viewing

Attending, Voting and Viewing the Annual General Meeting

Attending and Voting in Person at the Annual General Meeting

- AGM is at 12:00 p.m. CEST on 13 May 2026.
- Location: Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland
- Shareholders wishing to attend and vote at the 2026 Annual General Meeting in person must present proof of ownership (or a valid legal proxy) and a valid government issued identification document at the 2026 Annual General Meeting.

Voting through proxy / providing electronic voting instructions

- Shares held on Nasdaq US: Managed by Broadridge
- Shares held on Nasdaq Iceland: Voting through Lumi AGM Mobile Platform

Broadcast

- The 2026 Annual General Meeting will be broadcast for viewing only, with no option for virtual participation.
- View AGM broadcast through Lumi: <https://meetings.lumiconnect.com/100-352-684-319>

Voting through proxy / providing electronic voting instructions

	Shares held on Nasdaq US		Shares held on Nasdaq Iceland
Managed by	Broadridge		Lumi AGM Mobile Platform
Ownership type	Shares held via broker	Shares held directly (registered/Continental)	n/a
How you receive voting info	Via broker (email/letter with Broadridge link)	By email/letter from Broadridge	Register for voting on: www.lumiconnect.com/events/oculisagm2026
How you vote	1) Online on proxyvote.com using control number received along with voting information 2) By sending proxy by mail to Broadridge		Online using login credentials received by e-mail after registration is confirmed by Lumi
Deadline	Voting instructions must be received by Broadridge no later than 23:59 EDT on 11 May 2026		Submit voting instructions by 23:59 EDT on 11 May 2026 on the Lumi platform

7. Q&A Session 2

Thank you



Oculis | Visionary
Innovation